TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) today announced that certain aspects of its predictive approach to therapeutics discovery as applied to novel immune checkpoints will be presented in poster sessions at three leading scientific conferences this month and next. The presentations also include experimental results from some of the immune checkpoint based product candidate programs addressing cancer immunotherapy and autoimmune diseases now being pursued by the Company:
Help employers find you! Check out all the jobs and post your resume.
